Effect of alpha-adrenergic blockers, ACE inhibitors, and calcium channel antagonists on renal function in hypertensive non-insulin-dependent diabetic patients
- PMID: 8852495
- DOI: 10.1159/000188911
Effect of alpha-adrenergic blockers, ACE inhibitors, and calcium channel antagonists on renal function in hypertensive non-insulin-dependent diabetic patients
Abstract
In the present study we investigated the effect of a selective alpha 1-adrenergic blocker (doxazosin), an angiotensin-converting enzyme (ACE) inhibitor (captopril), and a calcium channel antagonist (nifedipine) on renal function in hypertensive non-insulin-dependent diabetic patients. 30 NIDD hypertensive patients (age = 50 +/- 3 years; BMI = 30 +/- 1 kg/m2) (mean +/- SEM) were studied before and after a 12-week period of antihypertensive treatment. Ten patients were treated with doxazosin (Cardura) (2-8 mg once daily or 8 mg b.i.d.), 9 with captopril (Capoten) (25-50 mg b.i.d.), and 11 with nifedipine (Procardia-XL) (30-60 mg once daily). Blood pressure, creatinine clearance, 24-hour urinary protein excretion, fasting plasma glucose concentration and glycosylated hemoglobin were measured before and after drug treatment. Fasting plasma glucose and glycosylated hemoglobin (HbA1c) were similar in all three groups prior to the start of antihypertensive therapy and did not change significantly from baseline in any treatment groups. In the doxazosin group creatinine clearance rose from 99 +/- 8 to 122 +/- 8 ml/1.73 m2.min (p < 0.01), while 24-hour urinary protein excretion declined from 2.66 +/- 0.05 to 1.76 +/- 0.02 mg/day/ml/1.73 m2.min (p < 0.01). In diabetics treated with captopril creatinine clearance rose from 93 +/- 6 to 109 +/- 9 ml/1.73 m2.min (p < 0.05), while the 24-hour urinary protein excretion fell from 2.70 +/- 0.05 to 2.03 +/- 0.04 mg/day/ml/1.73 m2.min (p < 0.05). In patients treated with nifedipine creatinine clearance did not change (97 +/- 6 vs. 94 +/- 7 ml/1.73 m2.min), while 24-hour urinary protein excretion decreased from 2.84 +/- 0.04 to 1.95 +/- 0.03 mg/day/ml/1.73 m2.min. Systolic and diastolic blood pressure were similar in doxazosin (150 +/- 3/95 +/- 2 mm Hg), captopril (153 +/- 3/93 +/- 1), and nifedipine (155 +/- 4/93 +/- 1) groups prior to the start of antihypertensive therapy and declined to 143 +/- 3/84 +/- 3 (doxazosin), 139 +/- 3/82 +/- 3 (captopril), and 141 +/- 3/84 +/- 1 (nifedipine) mm Hg (all p < 0.01 vs. pretreatment). In summary, both doxazosin and captopril treatment were associated with significant rises in GFR, while all three antihypertensive agents caused a significant decline in proteinuria. These results indicate that alpha-adrenergic blockers, ACE inhibitors, and calcium channel antagonists can safely and effectively be used in the clinical management of non-insulin-dependent diabetic patients with hypertension.
Similar articles
-
Effects of angiotensin-converting enzyme inhibitors, Ca2+ channel antagonists, and alpha-adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension.Diabetes. 1995 Jun;44(6):665-71. doi: 10.2337/diab.44.6.665. Diabetes. 1995. PMID: 7789631
-
Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.Nutr Metab Cardiovasc Dis. 2006 Mar;16(2):137-47. doi: 10.1016/j.numecd.2005.04.005. Epub 2005 Oct 20. Nutr Metab Cardiovasc Dis. 2006. PMID: 16487914 Clinical Trial.
-
Effect of nifedipine, captopril and prazosin on secretory function of pancreatic beta-cells in hypertensive patients with type-2 (non-insulin-dependent) diabetes and in hypertensive non-diabetics.Diabetes Res Clin Pract. 1996 Jun;33(1):59-66. doi: 10.1016/0168-8227(96)01258-2. Diabetes Res Clin Pract. 1996. PMID: 8877277
-
Renal protection and antihypertensive drugs: current status.Drugs. 1999 May;57(5):665-93. doi: 10.2165/00003495-199957050-00002. Drugs. 1999. PMID: 10353294 Review.
-
Effects of nitrendipine and other calcium antagonists on glucose metabolism in man.J Cardiovasc Pharmacol. 1984;6 Suppl 7:S986-95. J Cardiovasc Pharmacol. 1984. PMID: 6085390 Review.
Cited by
-
Dihydropyridine calcium channel blockers and renal disease.Hypertens Res. 2017 Jan;40(1):21-28. doi: 10.1038/hr.2016.85. Epub 2016 Jul 14. Hypertens Res. 2017. PMID: 27412800 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical
Miscellaneous